PD-L1 expression in medulloblastoma: an evaluation by subgroup
暂无分享,去创建一个
J. Taube | C. Drake | J. Hicks | P. Burger | L. Sullivan | D. Pardoll | A. Meeker | C. Eberhart | M. Santi | E. Raabe | M. Lim | Haiying Xu | J. Phallen | D. Martinez | C. Nirschl | K. Cohen | Thomas R. Nirschl | Sarah Harris-Bookman | M. Polanczyk | A. Ogurtsova | W. Bell | Allison M Martin | Eric H. Raabe | Aleksandra Ogurtsova
[1] M. Kool,et al. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma , 2017, Oncoimmunology.
[2] S. Miyamoto,et al. High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma. , 2017, Journal of neurosurgery.
[3] P. Sorensen,et al. Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues , 2017, Cancer.
[4] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[5] C. Porta,et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups , 2017, Annals of Oncology.
[6] Toby C. Cornish,et al. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy , 2017, JAMA oncology.
[7] Haiying Xu,et al. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison , 2017, Clinical Cancer Research.
[8] C. Drake,et al. LAG3 (CD223) as a cancer immunotherapy target , 2017, Immunological reviews.
[9] P. Brown,et al. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade , 2017, Cancer Immunology Research.
[10] J. Lunceford,et al. IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .
[11] Sam W. Lee,et al. Emerging roles of p53 and other tumour-suppressor genes in immune regulation , 2016, Nature Reviews Immunology.
[12] B. Coyle,et al. In vitro models of medulloblastoma: Choosing the right tool for the job. , 2016, Journal of biotechnology.
[13] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[14] Juanita Lopez,et al. Immuno-oncology combinations: raising the tail of the survival curve , 2016, Cancer biology & medicine.
[15] G. Freeman,et al. Learning from PD-1 Resistance: New Combination Strategies. , 2016, Trends in molecular medicine.
[16] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[17] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[18] J. Mesirov,et al. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets , 2016, Clinical Cancer Research.
[19] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[20] G. Calin,et al. PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.
[21] G. Gibney,et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[23] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[24] R. McLendon,et al. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma , 2015, Clinical Cancer Research.
[25] Xue Han,et al. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.
[26] J. Taube,et al. PD-1/PD-L1 inhibitors. , 2015, Current opinion in pharmacology.
[27] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[28] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[29] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[30] C. Drake,et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.
[31] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[32] Marzieh Vali,et al. Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas , 2014, Clinical Cancer Research.
[33] J. Taube,et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. , 2014 .
[34] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[35] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[36] S. Yip,et al. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. , 2013, Cancer research.
[37] David T. W. Jones,et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[39] P. Carmeliet,et al. Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma , 2013, Cell.
[40] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[41] Peter Vogel,et al. Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .
[42] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[43] B. Ksander,et al. Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80 , 2011, The Journal of Immunology.
[44] F. Aoudjit,et al. MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis , 2011, The Journal of Immunology.
[45] Hendrik Witt,et al. Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Arie Perry,et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.
[47] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] D. Getnet,et al. Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1 , 2009, The Journal of Immunology.
[49] B. Dale,et al. Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II , 2008 .
[50] T. MacDonald,et al. Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.
[51] M. Stastny,et al. Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells , 2007, Journal of pediatric hematology/oncology.
[52] C. Keet,et al. Medulloblastoma Simulating Acute Myeloid Leukemia: Case Report With a Review of “Myeloid Antigen” Expression in Nonhematopoietic Tissues and Tumors , 2006, Journal of pediatric hematology/oncology.
[53] C. Dang,et al. c-myc overexpression causes anaplasia in medulloblastoma. , 2006, Cancer research.
[54] L. Dušek,et al. Craniospinal irradiation of medulloblastoma in the supine position , 2006 .
[55] Lieping Chen,et al. B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.
[56] J. Krieger,et al. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN‐γ‐inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+ T‐cell activation , 2001, Glia.
[57] M. Gujrati,et al. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. , 1996, The American journal of surgical pathology.
[58] G. E. Keles,et al. Establishment and characterization of four human medulloblastoma-derived cell lines. , 1995, Oncology research.
[59] J. Trojanowski,et al. Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[60] W. J. Oakes,et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. , 1990, Cancer research.
[61] H. Mogami,et al. Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. , 1989, Cancer research.
[62] J. Trojanowski,et al. Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med , 1985, Journal of neuropathology and experimental neurology.
[63] J. Papadimitriou,et al. Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice , 1985, Journal of neuropathology and experimental neurology.
[64] R. Morantz,et al. Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors. , 1979, Journal of the National Cancer Institute.